1
Clark David Alan, Hulin Bernard, Goldstein Steven Wayne: Hypoglycemic thiazolidinedione derivatives.. Pfizer, September 13, 1989: EP0332332-A1 (46 worldwide citation)

Hypoglycemic thiazolidine-2,4-dione derivatives wherein the dotted line represents a bond or no bond; V is -CH=CH-, -N=CH-, -CH=N- or S; W is CH2, CHOH, CO, C=NOR or -CH=CH-; X is S, O, NR, -CH=N- or -N=CH-; Y is CH or N; Z is hydrogen, (C1-C7)alkyl, (C3-C7)cycloalkyl, phenyl, naphthyl, pyridyl, fur ...


2
David A Clark, Steven W Goldstein, Bernard Hulin: Hypoglycemic thiazolidinedione derivatives. Pfizer, J Trevor Lumb, Robert K Blackwood, Richardson Peter C, July 30, 1991: US05036079 (26 worldwide citation)

Hypoglycemic thiazolidine-2,4-derivatives ##STR1## wherein the dotted line represents a bond or no bond; V is --CH.dbd.CH--, --N.dbd.CH--, --CH.dbd.N-- or S;


3
David A Clark, Steven W Goldstein, Bernard Hulin: Hypoglycemic thiazolidinedione derivatives. Pfizer, Peter C Richardson, J Trevor Lumb, Mervin E Brokke, July 14, 1992: US05130379 (14 worldwide citation)

Hypoglycemic thiazolidine-2,4-dione derivatives ##STR1## wherein the dotted line represents a bond or no bond;


4
Gary Mark Coppola, Yuki Iwaki, Rajeshri Karki, Toshio Kawanami, Gary Michael Ksander, Muneto Mogi, Robert Sun: Substituted aminobutyric derivatives as neprilysin inhibitors. Novartis, Sophie Binet Cross, March 28, 2017: US09603819

The present invention provides a compound of formula I′; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, X and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further pro ...


5
Frederic Zecri, Philipp Grosche, Kayo Yasoshima, Hongjuan Zhao, Jun Yuan: Cyclic apelin derivatives for the treatment of heart failure. Novartis, Judith D Kuntz, March 6, 2018: US09908919

The invention provides a synthetic polypeptide of Formula I (SEQ ID NO: 1): X1-R-X3-R-L-X6-X7-K-X9-P-X11-X12-X13  I or an amide, an ester, a salt thereof, or a bioconjugate thereof, wherein X1, X3, X6, X7, X9, X11, X12 and X13 are defined herein. The polypeptides and bioconjugates are agonist of the ...


6
Hulin Bernard, Goldstein Steven Wayne, Clark David Alan: Hypoglycemiants derives de la thiazolidine dione, Hypoglycemic thiazolidinedione derivatives. Pfizer, SMART & BIGGAR, April 26, 1994: CA1328873

HYPOGLYCEMIC THIAZOLIDINEDIONE DERIVATIVES Abstract Hypoglycemic thiazolidine-2,4-dione derivatives Image ---(I)wherein the dotted line represents a bond or no bond; V is -CH=CH-, -N=CH-, -CH=N- or S;W is CH2, CHOH, CO, C=NOR or -CH=CH-;X is S, O, NR1, -CH=N- or -N=CH-;Y is CH or N;Z is hydrogen, (C ...


7
Bernard Hulin, David Alan Clark, Steven Wayne Goldstein: Hypoglycemic thiazolidinedione derivatives. Pfizer, WANG YANG WANG WEI, October 25, 1989: CN89101214

Hypoglycemic thiazolidine-2,4-dione derivatives of the formula I; or a pharmaceutically acceptable acid addition salt thereof when the compound contains a basic nitrogen.


8
Clark David A, Goldstein Steven W, Hulin Bernard: Hypoglycemic thiazolidinedione derivatives. Pfizer, Clark David A, Goldstein Steven W, Hulin Bernard, RICHARDSON Peter C, March 21, 1991: WO/1991/003474

Hypoglycemic thiazolidine-2,4-dione derivatives as in formula (I), wherein the dotted line represents a bond or no bond; V is -CH=CH-, -N=CH-, -CH=N- or S; W is CH¿2?, CHOH, CO, C=NOR or -CH=CH-; X is S, O, NR?1¿, -CH=N- or -N=CH-; Y is CH or N; Z is hydrogen, (C¿1?-C¿7?)alkyl, (C¿3?-C¿7?)cycloalkyl ...


9
Clark David A, Goldstein Steven W, Hulin Bernard: Hypoglycemic thiazolidinedione derivatives. Pfizer, Clark David A, Goldstein Steven W, Hulin Bernard, RICHARDSON Peter C, September 21, 1989: WO/1989/008651

Hypoglycemic thiazolidine-2,4-dione derivatives, of formula (I), wherein the dotted line represents a bond or no bonds; V is -CH=CH-, -N=CH-, -CH=N- or S; W is CH¿2?, CHOH, CO, C=NOR or -CH=CH-; X is S, O, NR?1¿, -CH=N- or -N=CH-; Y is CH or N; Z is hydrogen, (C¿1?-C¿7?)alkyl, (C¿3?-C¿7?)cycloalkyl, ...


10
SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP INHIBITORS. Novartis, January 19, 2017: US20170015688-A1

The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides p ...